Retina in rheumatic diseases: standard full field and multifocal electroretinography in hydroxychloroquine retinal dysfunction.
BACKGROUND
The purpose of this study was to evaluate and compare full-field electroretinography (ERG) and multifocal electroretinography (mfERG) results in detecting retinal dysfunction in a large number of asymptomatic patients treated with hydroxychloroquine (Hy).


METHODS
Fifty eyes in 50 patients with rheumatic diseases who had been using Hy for a period of time ranging from 30 months to 15 years, and 25 eyes in 25 healthy controls, were evaluated. Receiver operator characteristic (ROC) curves were calculated to determine the sensitivity and specificity of abnormal values in patients compared to the normal controls.


RESULTS
Signal depression was observed on the mfERG of Hy-treated patients. The most prevalent pattern was pericentral loss (19 eyes, 54.3 per cent), followed by full-field loss (11 eyes, 31.4 per cent), and central loss (five eyes, 14.3 per cent). Conversely, depression of the amplitude responses to the full field ERG was observed in only 16 per cent of the cases. The areas under the ROC curves ranged from 0.4056 to 0.9012, with the mfERG values having the largest areas, whereas the full-field ERG curves had the smallest area. The mfERG responses yielded the greatest sensitivity and specificity. In particular, the P1-N1 wave amplitude (ring 2) and root mean square (RMS) amplitude (ring 1) had specificities of 76 and 88 per cent, respectively, at sensitivities of 90 and 86 per cent.


CONCLUSIONS
A statistically significant retinal functional impairment was demonstrated by mfERG in the central two to 10 degrees in Hy-treated patients. Therefore, mfERG may provide an objective measurement of retinal dysfunction in patients receiving Hy therapy.
Centre of Ocular Electrophysiology, Department of Ophthalmology, University of Rome Sapienza, Italy. marcella.nebbioso@uniroma1.it
Marcella
M
Nebbioso
Maria L
ML
Livani
Robert D
RD
Steigerwalt
Valentina
V
Panetta
Eduardo
E
Rispoli
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects*; D004596:Electroretinography / Q000379:methods*; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012372:ROC Curve; D012164:Retinal Diseases / Q000175:diagnosis*; D012216:Rheumatic Diseases / Q000188:drug therapy*
D018501:Antirheumatic Agents; D006886:Hydroxychloroquine